Prime Medicine Inc (PRME)

Nov 26, 2024, 5:10 AM EST - 7 weeks ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Nov 21, 2024, 4:18 AM EST - 2 months ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Nov 6, 2024, 4:00 PM EST - 2 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

Oct 24, 2024, 8:00 AM EDT - 3 months ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 15, 2024, 8:00 AM EDT - 3 months ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Sep 30, 2024, 12:17 PM EDT - 3 months ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 8:38 AM EDT - 3 months ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Sep 30, 2024, 7:01 AM EDT - 3 months ago

Prime Medicine Unveils Strategically Focused Pipeline

May 13, 2024, 8:00 AM EDT - 8 months ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 12, 2024, 3:00 AM EDT - 8 months ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

May 10, 2024, 8:00 AM EDT - 9 months ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 8:00 AM EDT - 9 months ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 9 months ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 23, 2024, 8:00 AM EDT - 9 months ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Mar 1, 2024, 8:00 AM EST - 11 months ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 4:01 PM EST - 11 months ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 11:50 PM EST - 1 year ago

Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 4:05 PM EST - 1 year ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Jan 28, 2024, 8:11 AM EST - 1 year ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 25, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 1 year ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 5, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 2, 2024, 8:00 AM EST - 1 year ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 2:45 PM EST - 1 year ago

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

CRSP

Nov 8, 2023, 8:00 AM EST - 1 year ago

Prime Medicine to Present at Upcoming Investor Conferences

Nov 3, 2023, 4:01 PM EDT - 1 year ago

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 27, 2023, 6:00 AM EDT - 1 year ago

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Oct 24, 2023, 7:30 AM EDT - 1 year ago

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Sep 27, 2023, 8:49 AM EDT - 1 year ago

Prime Medicine: Not Yet Primed For Retail Investment

Aug 7, 2023, 4:01 PM EDT - 1 year ago

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 22, 2023, 8:00 AM EDT - 1 year ago

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

May 31, 2023, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at Investor Conferences in June

May 17, 2023, 4:05 PM EDT - 1 year ago

Prime Medicine to Present at Virtual Investor Conferences in May

May 17, 2023, 6:00 AM EDT - 1 year ago

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

May 11, 2023, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 23, 2023, 9:10 AM EDT - 1 year ago

Prime Medicine: Gene Editing Tech With Unique Approach

Mar 27, 2023, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days

Mar 9, 2023, 8:00 AM EST - 2 years ago

Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 27, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at Cowen 43rd Annual Health Care Conference

Jan 12, 2023, 12:15 AM EST - 2 years ago

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics

CRSP

Jan 4, 2023, 11:04 AM EST - 2 years ago

10 Potential 10x Return Stocks For The Next 10 Years

ABCL ASTS BEAM CRSP EDIT FROG HCP

Jan 3, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference

Oct 24, 2022, 7:52 PM EDT - 2 years ago

Prime Medicine: CRISPR 3.0 Company

Oct 24, 2022, 5:30 PM EDT - 2 years ago

Prime Medicine Announces Closing of Upsized Initial Public Offering

Oct 19, 2022, 9:47 PM EDT - 2 years ago

Prime Medicine Announces Pricing of Upsized Initial Public Offering

Oct 14, 2022, 2:30 PM EDT - 2 years ago

IPO Update: Prime Therapeutics Readies $151 Million U.S. IPO

Oct 13, 2022, 11:40 AM EDT - 2 years ago

Prime Medicine sets IPO terms, which could value the biotech at up to $1.7 billion

Sep 27, 2022, 2:45 PM EDT - 2 years ago

Gene Therapy Biotech Prime Medicine Begins U.S. IPO Effort